2. Search Result
Search Result
Results for "

Hypoglycemic effect

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1429
    Chlorpropamide
    2 Publications Verification

    		 Na+/K+ ATPase Metabolic Disease Endocrinology
    Chlorpropamide is an oral hypoglycemic agent that can influence acetaldehyde metabolism in mice and has a potentiating effect on antidiuretic hormone .
    Chlorpropamide
  • HY-N7377
    Butyl isobutyl phthalate

    		Glycosidase Metabolic Disease
    Butyl isobutyl phthalate is isolated from the rhizoid of Laminaria japonica. Butyl isobutyl phthalate is a non-competitive α-glucosidase inhibitor with an IC50 value of 38 μM. Butyl isobutyl phthalate shows a hypoglycemic effect and has the potential for diabetes treatment .
    Butyl isobutyl phthalate
  • HY-P4860
    Adropin (34-76) (human, mouse, rat)

    		Akt Gli JNK PKA Metabolic Disease
    Adropin (34-76) is a secretory domain of Adropin. Adropin (34-76) can inhibit cAMP level and glucose production in hepatocytes, and has a hypoglycemic effect. Adropin (34-76) plays an antifibrotic role by inhibiting the GLI1 signaling pathway .
    Adropin (34-76) (human, mouse, rat)
  • HY-162136
    GPR40 agonist 7

    		Free Fatty Acid Receptor Metabolic Disease
    GPR40 agonist 7 (Compound 1) is an orally active G protein-coupled receptor 40 (GPR40) agonist. GPR40 agonist 7 can significantly increase insulin and GLP-1 secretion, and has a hypoglycemic effect in vivo with an ED50 of 0.58 mg/kg
    GPR40 agonist 7
  • HY-150723
    PBI-6DNJ

    		Glycosidase Metabolic Disease
    PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a Ki of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research .
    PBI-6DNJ
  • HY-144713
    PTP1B-IN-16

    		Phosphatase Metabolic Disease
    PTP1B-IN-16 (Compound 46), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 12.6 μM. PTP1B-IN-16 can be used for the research of type 2 diabetes.
    PTP1B-IN-16
  • HY-144718
    PTP1B-IN-17

    		Phosphatase Metabolic Disease
    PTP1B-IN-17 (Compound 45), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 30.2 μM. PTP1B-IN-17 can be used for the research of type 2 diabetes.
    PTP1B-IN-17
  • HY-144716
    PTP1B-IN-19

    		Phosphatase Metabolic Disease
    PTP1B-IN-19 (Compound 43), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 23.3 μM. PTP1B-IN-19 can be used for the research of type 2 diabetes.
    PTP1B-IN-19

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: